Rituximab and its use in autoimmune bullous disorders

Benjamin S Daniel; Dédée F Murrell; Pascal Joly

doi:10.1016/j.det.2011.06.023

Rituximab and its use in autoimmune bullous disorders

Dermatol Clin. 2011 Oct;29(4):571-5. doi: 10.1016/j.det.2011.06.023.

Authors

Benjamin S Daniel¹, Dédée F Murrell, Pascal Joly

Affiliation

¹ Department of Dermatology, St George Hospital, Gray Street, Kogarah, Sydney, NSW 2217, Australia.

PMID: 21925000
DOI: 10.1016/j.det.2011.06.023

Abstract

Rituximab is a chimeric, murine-human, monoclonal antibody against the CD20 antigen of B lymphocytes. It has been used off-label to treat and manage autoimmune and dermatologic diseases as an alternative or adjuvant therapy to systemic treatments. Due to cost, potential complications, and lack of data rituximab is used after standard systemic therapies have failed or the patient is absolutely contraindicated for corticosteroids. More research is required.

MeSH terms

Antibodies, Monoclonal, Murine-Derived / adverse effects
Antibodies, Monoclonal, Murine-Derived / therapeutic use*
Antigens, CD20 / drug effects
Autoimmune Diseases / drug therapy*
B-Lymphocytes / drug effects
Dermatologic Agents / adverse effects
Dermatologic Agents / therapeutic use*
Female
Humans
Immunologic Factors / adverse effects
Immunologic Factors / therapeutic use*
Male
Rituximab
Skin Diseases, Vesiculobullous / drug therapy*
Treatment Outcome

Substances

Antibodies, Monoclonal, Murine-Derived
Antigens, CD20
Dermatologic Agents
Immunologic Factors
Rituximab